Huang T, Zhang K, Sun L, Xue X, Zhang C, Shu Z, Mu N, Gu J, Zhang W, Wang Y, Zhang Y, Zhang W
Here's an overview of the safety profile based on available evidence: Minimal Toxicity Minimal Toxicity Studies conducted prior to clinical trials have consistently found that BPC-157 has low toxicity when administered, with even high doses being well-tolerated by animals and showing no significant negative effects
Uroplakin peptide-specific autoimmunity initiates interstitial cystitis/painful bladder syndrome in mice
The possible mechanism might be associated with the regulation of iron-treated proteins, enhancement of antioxidant capacity (Zhang et al., 2018), inhibition of the activation and apoptosis of MAPK, and STAT3 under iron overload (Song et al., 2020)